0 CHECKOUT

Dysmenorrhea - Pipeline Review, H1 2015

  • ID: 3275733
  • May 2015
  • 34 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Merck & Co., Inc.
  • ObsEva SA
  • PDC Biotech GmbH
  • MORE

Dysmenorrhea - Pipeline Review, H1 2015

Summary

The‘Dysmenorrhea - Pipeline Review, H1 2015’, provides an overview of the Dysmenorrhea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dysmenorrhea and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Merck & Co., Inc.
  • ObsEva SA
  • PDC Biotech GmbH
  • MORE

List of Tables

List of Figures

Introduction

Report Coverage

Dysmenorrhea Overview

Therapeutics Development

Pipeline Products for Dysmenorrhea - Overview

Pipeline Products for Dysmenorrhea - Comparative Analysis

Dysmenorrhea - Therapeutics under Development by Companies

Dysmenorrhea - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Dysmenorrhea - Products under Development by Companies

Dysmenorrhea - Companies Involved in Therapeutics Development

Merck & Co., Inc.

ObsEva SA

PDC Biotech GmbH

Thar Pharmaceuticals, Inc.

Dysmenorrhea - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

MK-8342B - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OBE-002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PDC-41 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptidometics - Drug Profile

Product Description

Mechanism of Action

R&D Progress

T-109 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dysmenorrhea - Dormant Projects

Dysmenorrhea - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Dysmenorrhea, H1 2015

Number of Products under Development for Dysmenorrhea - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Dysmenorrhea - Pipeline by Merck & Co., Inc., H1 2015

Dysmenorrhea - Pipeline by ObsEva SA, H1 2015

Dysmenorrhea - Pipeline by PDC Biotech GmbH, H1 2015

Dysmenorrhea - Pipeline by Thar Pharmaceuticals, Inc., H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Dysmenorrhea - Dormant Projects, H1 2015

Dysmenorrhea - Discontinued Products, H1 2015

List of Figures:

Number of Products under Development for Dysmenorrhea, H1 2015

Number of Products under Development for Dysmenorrhea - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Merck & Co., Inc.
- ObsEva SA
- PDC Biotech GmbH
- Thar Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S